Document is current

Documents that mention this clinical trial

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
https://doi.org/10.1136/jitc-2020-000650

73 Delta-radiomics predicts response and overall survival in advanced non-small cell lung cancer patients treated with durvalumab
https://doi.org/10.1136/jitc-2022-sitc2022.0073

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705

579 Novel digital image approach of multiplex immunofluorescence based PD-L1 expression enables the stratification of advanced NSCLC patients treated with durvalumab
https://doi.org/10.1136/jitc-2022-sitc2022.0579

365 Computational pathology delivers objective and quantitative PD-L1 expression analysis for enrichment of responders to durvalumab in non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.365

269 Tumoral and peripheral landscape of Viral- versus Carcinogen-Driven Head and Neck Cancer
https://doi.org/10.1136/jitc-2020-sitc2020.0269

583 Quantitative computational assessment of PD-L1 enables robust patient selection for biomarker-informed anti-PD-L1 treatment of NSCLC patients
https://doi.org/10.1136/jitc-2022-sitc2022.0583

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1

605 Computational pathology-based digital twins enable the discovery of predictive biomarkers for precision immuno-oncology
https://doi.org/10.1136/jitc-2023-sitc2023.0605

Checkpoint Inhibitors in Head and Neck Cancer: Current Knowledge and Perspectives
https://doi.org/10.1136/jim-2018-000743

674 Late antibiotic administration during durvalumab treatment may be associated with clinical benefit
https://doi.org/10.1136/jitc-2020-sitc2020.0674

591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552

Clinical Validation of Mathematically Derived Early Tumor Dynamics for Solid Tumors in Response to Durvalumab
https://doi.org/10.1200/cci.23.00254